| LEADER |
03334nam a22003257a 4500 |
| 001 |
1506205 |
| 041 |
|
|
|a eng
|
| 100 |
|
|
|9 536690
|a Al-Adami, Salat Ghassan Husni
|e Author
|
| 245 |
|
|
|a Modulation of Doxorubicin Cytotoxicity by Iso-liquiritin and Cynarin Combination on Different Cancer Cell Lines
|
| 260 |
|
|
|a السلط
|c 2017
|
| 300 |
|
|
|a 1 - 138
|
| 336 |
|
|
|a رسائل جامعية
|
| 502 |
|
|
|b رسالة ماجستير
|c جامعة عمان الأهلية
|f كلية الصيدلة والعلوم الطبية
|g الاردن
|o 0016
|
| 520 |
|
|
|a Natural polyphenolic compounds produced by plant exhibit many pharmacological effects including antioxidant, chemo preventive as well as anticancer properties. This study was conducted to investigate the effect of cynarin (Artichoke, Cynara scolymus) and isoliquiritin (Licorice, Glycyrrhiza uralensis) on doxorubicin (positive control) cytotoxicity in different cell lines including normal (Fibroblasts MCR-5 and Myoblasts H9c2) and cancer (colorectal HCT-116 and hepatocellular HEP-G2) cell lines. The Cytotoxic effect of doxorubicin, isoliquiritin and cynarin alone or in different combination was studied on cancer cell lines as well as normal cell lines. The results obtained indicated that both cynarin and isoliquiritin enhance the cytotoxicity of doxorubicin. Both cynarin and isoliquiritin also reduce the cardio toxicity of doxorubicin on normal cardiac cell lines. The combination of the three drug (cynarin, isoliquiritin and doxorubicin) result in decrease the cytotoxicity of doxorubicin, which may indicate the presence of interaction and/or antagonism effect between cynarin and isoliquiritin. Cynarin was found to enhance the growth of (HCT-116 and HEP-G2) this might suggest avoiding use of Artichoke in subjects’ susceptibility for these cancers. All results were evaluated using statistical path and showed significant findings. The mechanism of enhanced doxorubicin’s cytotoxicity by cynarin or isoliquiritin also require further investigation to explain the increasing and/or the decreasing effect of these polyphenolic compounds on cytotoxicity of doxorubicin. The current finding can help to start with safe minimum dose of two or three combination compounds in the context of clinical trials and practice.
|
| 653 |
|
|
|a الأدوية والعقاقير
|a الخلايا السرطانية
|a السمية الخلوية
|a خلايا الدوكسوروبيسين
|a مزيج ايزوليترين والسينارين
|
| 700 |
|
|
|9 536693
|a المشهداني، نوفل نعمان
|g Al-Mashhdani, Nawfal
|e مشرف
|
| 700 |
|
|
|9 536614
|a الخطيب، إقبال حسن
|g Al-Khateeb, Eqbal H.
|e مشرف
|
| 856 |
|
|
|u 9802-028-002-0016-T.pdf
|y صفحة العنوان
|
| 856 |
|
|
|u 9802-028-002-0016-A.pdf
|y المستخلص
|
| 856 |
|
|
|u 9802-028-002-0016-C.pdf
|y قائمة المحتويات
|
| 856 |
|
|
|u 9802-028-002-0016-F.pdf
|y 24 صفحة الأولى
|
| 856 |
|
|
|u 9802-028-002-0016-1.pdf
|y 1 الفصل
|
| 856 |
|
|
|u 9802-028-002-0016-2.pdf
|y 2 الفصل
|
| 856 |
|
|
|u 9802-028-002-0016-3.pdf
|y 3 الفصل
|
| 856 |
|
|
|u 9802-028-002-0016-O.pdf
|y الخاتمة
|
| 856 |
|
|
|u 9802-028-002-0016-R.pdf
|y المصادر والمراجع
|
| 856 |
|
|
|u 9802-028-002-0016-S.pdf
|y الملاحق
|
| 930 |
|
|
|d y
|
| 995 |
|
|
|a Dissertations
|
| 999 |
|
|
|c 995402
|d 995402
|
